Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
HP group had significantly lower fat infiltration into thigh muscles (low-density CSA) and higher serum 25(OH)D, REE.
Source: Study characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Review / evidence synthesis.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Post-stroke sarcopenia as a neuromuscular disorder: a mini review of neural mechanisms and clinical implications
Source: Article title.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Post-stroke sarcopenia as a neuromuscular disorder: a mini review of neural mechanisms and clinical implications
Review / evidence synthesis · Frontiers in Neurology · 2026
Original publication title
Post-stroke sarcopenia as a neuromuscular disorder: a mini review of neural mechanisms and clinical implications
Copyright © 2026 Yang and Deng.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
To systematically review the neural mechanisms underlying post-stroke sarcopenia and synthesize evidence on its clinical implications, diagnostic approaches, and therapeutic interventions.
Source: ObjectiveAbstract: What methods does the paper describe?
A mini review of the literature was conducted, synthesizing evidence from key studies addressing neural mechanisms, pathophysiology, diagnosis, or treatment of post-stroke sarcopenia.
Source: MethodsAbstract: Results
Post-stroke sarcopenia affects 11%−67% of stroke survivors, with paretic limbs losing >30% muscle mass within 6 months. The pathophysiology involves a cascade from corticospinal tract damage to motor neuron degeneration, neuromuscular junction dysfunction, and muscle fiber atrophy. Key mechanisms include denervation-induced neurogenic atrophy, inflammatory dysregulation (IL-6, TNF-α, myostatin upregulation), and impaired IGF-1/Akt/mTOR signaling. Asymmetric muscle loss patterns distinguish this condition from primary sarcopenia. Diagnostic approaches combine imaging (DXA, BIA, CT), functional assessments (grip strength, gait speed, SPPB), and stroke-specific criteria.
Multimodal interventions including neuromuscular electrical stimulation, resistance training, nutritional support, and spasticity management show promise.
Source: ResultsAbstract: Conclusions
Post-stroke sarcopenia is a neurogenic disorder requiring distinct diagnostic criteria and targeted interventions. Early recognition and multidisciplinary management are essential for optimizing functional recovery and reducing disability burden.
Source: ConclusionsAuthors’ abstract
Background
Post-stroke sarcopenia represents a distinct neuromuscular disorder characterized by progressive muscle loss and functional decline. Unlike age-related sarcopenia, stroke-induced muscle wasting involves specific neural mechanisms originating from central nervous system injury.
Objective
To systematically review the neural mechanisms underlying post-stroke sarcopenia and synthesize evidence on its clinical implications, diagnostic approaches, and therapeutic interventions.
Methods
A mini review of the literature was conducted, synthesizing evidence from key studies addressing neural mechanisms, pathophysiology, diagnosis, or treatment of post-stroke sarcopenia.
Results
Post-stroke sarcopenia affects 11%−67% of stroke survivors, with paretic limbs losing >30% muscle mass within 6 months. The pathophysiology involves a cascade from corticospinal tract damage to motor neuron degeneration, neuromuscular junction dysfunction, and muscle fiber atrophy. Key mechanisms include denervation-induced neurogenic atrophy, inflammatory dysregulation (IL-6, TNF-α, myostatin upregulation), and impaired IGF-1/Akt/mTOR signaling. Asymmetric muscle loss patterns distinguish this condition from primary sarcopenia. Diagnostic approaches combine imaging (DXA, BIA, CT), functional assessments (grip strength, gait speed, SPPB), and stroke-specific criteria.
Multimodal interventions including neuromuscular electrical stimulation, resistance training, nutritional support, and spasticity management show promise.
Conclusions
Post-stroke sarcopenia is a neurogenic disorder requiring distinct diagnostic criteria and targeted interventions. Early recognition and multidisciplinary management are essential for optimizing functional recovery and reducing disability burden.
Publication and source details
Original title: Post-stroke sarcopenia as a neuromuscular disorder: a mini review of neural mechanisms and clinical implications
Lin Yang; Sen-Jun Deng
Frontiers in Neurology · 2026
* Correspondence: Sen-Jun Deng, dengsenjun@hmc.edu.cnCopyright © 2026 Yang and Deng.2026Yang and Denghttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the Health Science and Technology Program of Zhejiang Provincial Health Commission (Grant No. 2025HY0090) and Zhejiang Traditional Chinese Medicine Administration (Grant No. 2024ZL272).Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T21:44:26.163816+00:00
DOI: 10.3389/fneur.2026.1885542 · PMC13584865